Target miss using PTV-based IMRT compared to robust optimization via coverage probability concept in prostate cancer

Purpose: Cure- and toxicity rates of prostate IGRT can both be affected by ill-chosen planning target volume (PTV) margins. For dose-escalated prostate radiotherapy, we studied the potential for organ at risk (OAR) sparing and compensation of prostate motion with robust plan optimization using the c...

Full description

Saved in:
Bibliographic Details
Published inActa oncologica Vol. 59; no. 8; pp. 911 - 917
Main Authors Outaggarts, Zoulikha, Wegener, Daniel, Berger, Bernhard, Zips, Daniel, Paulsen, Frank, Bleif, Martin, Thorwarth, Daniela, Alber, Markus, Dohm, Oliver, Müller, Arndt-Christian
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 02.08.2020
Online AccessGet full text
ISSN0284-186X
1651-226X
1651-226X
DOI10.1080/0284186X.2020.1760349

Cover

Abstract Purpose: Cure- and toxicity rates of prostate IGRT can both be affected by ill-chosen planning target volume (PTV) margins. For dose-escalated prostate radiotherapy, we studied the potential for organ at risk (OAR) sparing and compensation of prostate motion with robust plan optimization using the coverage probability (CovP) concept compared to conventional PTV-based IMRT. Material and methods: We evaluated plan quality of CovP-plans for 27 intermediate risk prostate cancer patients treated in a prospective study (78 Gy/39 fractions). Clinical target volume (CTV) and OARs were contoured on three separate CTs to capture movement and deformation. To define the internal target volume (ITV), the union of CTV1-3 was encompassed by an isotropic margin of 7 mm for the planning process. CovP-dose distribution is optimized considering weight factors for IMRT constraints derived from probabilities of systematic organ displacement in the three CTs. CovP-dose volume histograms (DVHs) were compared with additionally calculated conventional PTV-based IMRT plans. PTV-based IMRT was planned on one-single CT with an isotropically expanded CTV to generate the PTV (i.e., CTV1 + 7mm) and was evaluated on the two other CTs. Results: The CovP-concept showed higher robustness in target volume coverage. Target miss was frequently observed with PTV-based IMRT, resulting in cold spots until 70 Gy with the CovP-concept. The target dose at 74 Gy was comparable, while further the dose-escalation (75-78 Gy) was improved with PTV-based IMRT. However, dose-escalation with PTV-based IMRT was associated with increased OAR-doses, especially in high-dose areas. Conclusions: Probabilistic dose-escalated IMRT was feasible in this prospective study. Comparison of the CovP-concept with PTV-based IMRT revealed superiority with regard to target-coverage and sparing of OARs. The CovP-concept implements a robust plan optimization strategy for organ deformation and motions and could, therefore, serve as a less demanding compromise on the way to adaptive IGRT avoiding daily time-consuming re-planning. SUMMARY We evaluated the robustness of coverage probability (CovP)-based IMRT plans within a prospective study for prostate cancer radiotherapy. The treatment plans were compared with newly calculated conventional PTV-based IMRT plans. We were able to show that CovP led to a clearly more robust target coverage by avoiding hot spots at OARs compared to conventional PTV-based IMRT. In addition, negative consequences of an inflated PTV can be ameliorated by a more relaxed CovP-based dose prescription.
AbstractList Cure- and toxicity rates of prostate IGRT can both be affected by ill-chosen planning target volume (PTV) margins. For dose-escalated prostate radiotherapy, we studied the potential for organ at risk (OAR) sparing and compensation of prostate motion with robust plan optimization using the coverage probability (CovP) concept compared to conventional PTV-based IMRT. We evaluated plan quality of CovP-plans for 27 intermediate risk prostate cancer patients treated in a prospective study (78 Gy/39 fractions). Clinical target volume (CTV) and OARs were contoured on three separate CTs to capture movement and deformation. To define the internal target volume (ITV), the union of CTV1-3 was encompassed by an isotropic margin of 7 mm for the planning process. CovP-dose distribution is optimized considering weight factors for IMRT constraints derived from probabilities of systematic organ displacement in the three CTs. CovP-dose volume histograms (DVHs) were compared with additionally calculated conventional PTV-based IMRT plans. PTV-based IMRT was planned on one-single CT with an isotropically expanded CTV to generate the PTV (i.e., CTV1 + 7mm) and was evaluated on the two other CTs. The CovP-concept showed higher robustness in target volume coverage. Target miss was frequently observed with PTV-based IMRT, resulting in cold spots until 70 Gy with the CovP-concept. The target dose at 74 Gy was comparable, while further the dose-escalation (75-78 Gy) was improved with PTV-based IMRT. However, dose-escalation with PTV-based IMRT was associated with increased OAR-doses, especially in high-dose areas. Probabilistic dose-escalated IMRT was feasible in this prospective study. Comparison of the CovP-concept with PTV-based IMRT revealed superiority with regard to target-coverage and sparing of OARs. The CovP-concept implements a robust plan optimization strategy for organ deformation and motions and could, therefore, serve as a less demanding compromise on the way to adaptive IGRT avoiding daily time-consuming re-planning. SUMMARYWe evaluated the robustness of coverage probability (CovP)-based IMRT plans within a prospective study for prostate cancer radiotherapy. The treatment plans were compared with newly calculated conventional PTV-based IMRT plans. We were able to show that CovP led to a clearly more robust target coverage by avoiding hot spots at OARs compared to conventional PTV-based IMRT. In addition, negative consequences of an inflated PTV can be ameliorated by a more relaxed CovP-based dose prescription.
Purpose: Cure- and toxicity rates of prostate IGRT can both be affected by ill-chosen planning target volume (PTV) margins. For dose-escalated prostate radiotherapy, we studied the potential for organ at risk (OAR) sparing and compensation of prostate motion with robust plan optimization using the coverage probability (CovP) concept compared to conventional PTV-based IMRT. Material and methods: We evaluated plan quality of CovP-plans for 27 intermediate risk prostate cancer patients treated in a prospective study (78 Gy/39 fractions). Clinical target volume (CTV) and OARs were contoured on three separate CTs to capture movement and deformation. To define the internal target volume (ITV), the union of CTV1-3 was encompassed by an isotropic margin of 7 mm for the planning process. CovP-dose distribution is optimized considering weight factors for IMRT constraints derived from probabilities of systematic organ displacement in the three CTs. CovP-dose volume histograms (DVHs) were compared with additionally calculated conventional PTV-based IMRT plans. PTV-based IMRT was planned on one-single CT with an isotropically expanded CTV to generate the PTV (i.e., CTV1 + 7mm) and was evaluated on the two other CTs. Results: The CovP-concept showed higher robustness in target volume coverage. Target miss was frequently observed with PTV-based IMRT, resulting in cold spots until 70 Gy with the CovP-concept. The target dose at 74 Gy was comparable, while further the dose-escalation (75-78 Gy) was improved with PTV-based IMRT. However, dose-escalation with PTV-based IMRT was associated with increased OAR-doses, especially in high-dose areas. Conclusions: Probabilistic dose-escalated IMRT was feasible in this prospective study. Comparison of the CovP-concept with PTV-based IMRT revealed superiority with regard to target-coverage and sparing of OARs. The CovP-concept implements a robust plan optimization strategy for organ deformation and motions and could, therefore, serve as a less demanding compromise on the way to adaptive IGRT avoiding daily time-consuming re-planning. SUMMARY We evaluated the robustness of coverage probability (CovP)-based IMRT plans within a prospective study for prostate cancer radiotherapy. The treatment plans were compared with newly calculated conventional PTV-based IMRT plans. We were able to show that CovP led to a clearly more robust target coverage by avoiding hot spots at OARs compared to conventional PTV-based IMRT. In addition, negative consequences of an inflated PTV can be ameliorated by a more relaxed CovP-based dose prescription.
Purpose: Cure- and toxicity rates of prostate IGRT can both be affected by ill-chosen planning target volume (PTV) margins. For dose-escalated prostate radiotherapy, we studied the potential for organ at risk (OAR) sparing and compensation of prostate motion with robust plan optimization using the coverage probability (CovP) concept compared to conventional PTV-based IMRT.Material and methods: We evaluated plan quality of CovP-plans for 27 intermediate risk prostate cancer patients treated in a prospective study (78 Gy/39 fractions). Clinical target volume (CTV) and OARs were contoured on three separate CTs to capture movement and deformation. To define the internal target volume (ITV), the union of CTV1-3 was encompassed by an isotropic margin of 7 mm for the planning process. CovP-dose distribution is optimized considering weight factors for IMRT constraints derived from probabilities of systematic organ displacement in the three CTs. CovP-dose volume histograms (DVHs) were compared with additionally calculated conventional PTV-based IMRT plans. PTV-based IMRT was planned on one-single CT with an isotropically expanded CTV to generate the PTV (i.e., CTV1 + 7mm) and was evaluated on the two other CTs.Results: The CovP-concept showed higher robustness in target volume coverage. Target miss was frequently observed with PTV-based IMRT, resulting in cold spots until 70 Gy with the CovP-concept. The target dose at 74 Gy was comparable, while further the dose-escalation (75-78 Gy) was improved with PTV-based IMRT. However, dose-escalation with PTV-based IMRT was associated with increased OAR-doses, especially in high-dose areas.Conclusions: Probabilistic dose-escalated IMRT was feasible in this prospective study. Comparison of the CovP-concept with PTV-based IMRT revealed superiority with regard to target-coverage and sparing of OARs. The CovP-concept implements a robust plan optimization strategy for organ deformation and motions and could, therefore, serve as a less demanding compromise on the way to adaptive IGRT avoiding daily time-consuming re-planning. SUMMARYWe evaluated the robustness of coverage probability (CovP)-based IMRT plans within a prospective study for prostate cancer radiotherapy. The treatment plans were compared with newly calculated conventional PTV-based IMRT plans. We were able to show that CovP led to a clearly more robust target coverage by avoiding hot spots at OARs compared to conventional PTV-based IMRT. In addition, negative consequences of an inflated PTV can be ameliorated by a more relaxed CovP-based dose prescription.Purpose: Cure- and toxicity rates of prostate IGRT can both be affected by ill-chosen planning target volume (PTV) margins. For dose-escalated prostate radiotherapy, we studied the potential for organ at risk (OAR) sparing and compensation of prostate motion with robust plan optimization using the coverage probability (CovP) concept compared to conventional PTV-based IMRT.Material and methods: We evaluated plan quality of CovP-plans for 27 intermediate risk prostate cancer patients treated in a prospective study (78 Gy/39 fractions). Clinical target volume (CTV) and OARs were contoured on three separate CTs to capture movement and deformation. To define the internal target volume (ITV), the union of CTV1-3 was encompassed by an isotropic margin of 7 mm for the planning process. CovP-dose distribution is optimized considering weight factors for IMRT constraints derived from probabilities of systematic organ displacement in the three CTs. CovP-dose volume histograms (DVHs) were compared with additionally calculated conventional PTV-based IMRT plans. PTV-based IMRT was planned on one-single CT with an isotropically expanded CTV to generate the PTV (i.e., CTV1 + 7mm) and was evaluated on the two other CTs.Results: The CovP-concept showed higher robustness in target volume coverage. Target miss was frequently observed with PTV-based IMRT, resulting in cold spots until 70 Gy with the CovP-concept. The target dose at 74 Gy was comparable, while further the dose-escalation (75-78 Gy) was improved with PTV-based IMRT. However, dose-escalation with PTV-based IMRT was associated with increased OAR-doses, especially in high-dose areas.Conclusions: Probabilistic dose-escalated IMRT was feasible in this prospective study. Comparison of the CovP-concept with PTV-based IMRT revealed superiority with regard to target-coverage and sparing of OARs. The CovP-concept implements a robust plan optimization strategy for organ deformation and motions and could, therefore, serve as a less demanding compromise on the way to adaptive IGRT avoiding daily time-consuming re-planning. SUMMARYWe evaluated the robustness of coverage probability (CovP)-based IMRT plans within a prospective study for prostate cancer radiotherapy. The treatment plans were compared with newly calculated conventional PTV-based IMRT plans. We were able to show that CovP led to a clearly more robust target coverage by avoiding hot spots at OARs compared to conventional PTV-based IMRT. In addition, negative consequences of an inflated PTV can be ameliorated by a more relaxed CovP-based dose prescription.
Author Alber, Markus
Thorwarth, Daniela
Bleif, Martin
Wegener, Daniel
Paulsen, Frank
Müller, Arndt-Christian
Zips, Daniel
Dohm, Oliver
Outaggarts, Zoulikha
Berger, Bernhard
Author_xml – sequence: 1
  givenname: Zoulikha
  surname: Outaggarts
  fullname: Outaggarts, Zoulikha
  organization: Department of Radiation Oncology, University Hospital Tübingen
– sequence: 2
  givenname: Daniel
  surname: Wegener
  fullname: Wegener, Daniel
  email: daniel.wegener@med.uni-tuebingen.de
  organization: Department of Radiation Oncology, University Hospital Tübingen
– sequence: 3
  givenname: Bernhard
  surname: Berger
  fullname: Berger, Bernhard
  organization: Clinic for Radiation Oncology, Oberschwaben Hospital Group
– sequence: 4
  givenname: Daniel
  surname: Zips
  fullname: Zips, Daniel
  organization: Department of Radiation Oncology, University Hospital Tübingen
– sequence: 5
  givenname: Frank
  surname: Paulsen
  fullname: Paulsen, Frank
  organization: Department of Radiation Oncology, University Hospital Tübingen
– sequence: 6
  givenname: Martin
  surname: Bleif
  fullname: Bleif, Martin
  organization: Clinic for Radiology and Radiation Oncology, ALB FILS Clinics Hospital on the Eichert
– sequence: 7
  givenname: Daniela
  surname: Thorwarth
  fullname: Thorwarth, Daniela
  organization: Department of Radiation Oncology, Section Medical Physics, University Hospital Tübingen
– sequence: 8
  givenname: Markus
  surname: Alber
  fullname: Alber, Markus
  organization: Clinic for Radiation Oncology, University Hospital Heidelberg
– sequence: 9
  givenname: Oliver
  surname: Dohm
  fullname: Dohm, Oliver
  organization: Department of Radiation Oncology, Section Medical Physics, University Hospital Tübingen
– sequence: 10
  givenname: Arndt-Christian
  orcidid: 0000-0002-6539-0682
  surname: Müller
  fullname: Müller, Arndt-Christian
  organization: Department of Radiation Oncology, University Hospital Tübingen
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32436467$$D View this record in MEDLINE/PubMed
BookMark eNqFkc1u1DAUha2qqJ0WHqGVl2zS-i-JIzagCtpKRSA0oO6sG8ceGSVxsJ2i4enrdKZdsICV5aPvXPuec4IORz8ahM4ouaBEkkvCpKCyur9ghGWprggXzQFa0aqkBWPV_SFaLUyxQMfoJMafhBDG6_IIHXMmeCWqeoXSGsLGJDy4GPEc3bjBX9c_ihai6fDt529rrP0wQci35HHw7RwT9lNyg_sDyfkRPzjIzIMJsDF4ygS0rndpm8VRmylhNy5yTJAM1pC18Bq9stBH82Z_nqLvnz6ur26Kuy_Xt1cf7gotKE-FqVmtiWgsa23-utQlFdySupOslqYztG0awmvJZEObshNgoRSWVowaymVe8RS93c3N7_-aTUwqr6lN38No_BwVE6TkPIfRZPR8j87tYDo1BTdA2KrnpDJQ7gCdd4nB2BeEErU0op4bUUsjat9I9r37y6ddekouBXD9f93vd243Wh8G-O1D36kE294HG3KYLir-7xGP1TikXQ
CitedBy_id crossref_primary_10_3390_cancers16050892
crossref_primary_10_1002_mp_17023
crossref_primary_10_2478_raon_2020_0075
crossref_primary_10_1016_j_phro_2022_02_013
Cites_doi 10.1371/journal.pone.0154499
10.1016/S0167-8140(18)31915-7
10.1016/j.radonc.2017.01.015
10.1016/j.clon.2012.05.002
10.1016/j.radonc.2016.04.014
10.1016/j.radonc.2017.10.029
10.1186/1471-2407-13-27
10.1016/j.zemedi.2016.02.002
10.1016/j.ijrobp.2006.07.013
10.1088/0031-9155/60/2/549
10.1016/j.radonc.2014.02.009
10.1016/j.ijrobp.2009.07.1754
10.1088/1361-6560/aae659
10.1016/S0360-3016(00)00700-8
10.1016/j.radonc.2005.06.006
10.1016/j.ijrobp.2008.10.091
10.1016/j.ijrobp.2009.01.062
10.1016/S1470-2045(16)30102-4
10.1016/j.radonc.2005.09.005
10.1016/S0360-3016(00)00608-8
ContentType Journal Article
Copyright 2020 Acta Oncologica Foundation 2020
Copyright_xml – notice: 2020 Acta Oncologica Foundation 2020
DBID AAYXX
CITATION
NPM
7X8
DOI 10.1080/0284186X.2020.1760349
DatabaseName CrossRef
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1651-226X
EndPage 917
ExternalDocumentID 32436467
10_1080_0284186X_2020_1760349
1760349
Genre Article
Journal Article
GroupedDBID ---
00X
03L
0BK
23M
2WC
36B
4.4
5GY
5RE
6J9
AALUX
AAMIU
AAPUL
AAWTL
ABDBF
ABEIZ
ABJNI
ABLIJ
ABLJU
ABLKL
ABNNA
ABUPF
ABXYU
ACENM
ACGEJ
ACGFO
ACGFS
ACIEZ
ACUHS
ADBBV
ADCVX
ADRBQ
ADXPE
AECIN
AEGXH
AENEX
AEOZL
AEXWM
AFKVX
AGDLA
AGFJD
AGYJP
AIAGR
AIJEM
AJWEG
AKBVH
ALMA_UNASSIGNED_HOLDINGS
ALQZU
ALYBC
BABNJ
BAWUL
BLEHA
BOHLJ
CCCUG
COF
CS3
DIK
DKSSO
EAP
EBB
EBC
EBD
EBS
EBX
EMB
EMK
EMOBN
EPL
ESX
F5P
GROUPED_DOAJ
GX1
H13
HZ~
KRBQP
KSSTO
KWAYT
KYCEM
L7B
LJTGL
M4Z
O9-
OK1
P2P
SV3
TBQAZ
TDBHL
TERGH
TFDNU
TFL
TFW
TUS
UEQFS
V1S
WH7
~1N
AAFWJ
AAYXX
AFPKN
CITATION
PGMZT
NPM
7X8
ID FETCH-LOGICAL-c413t-e727c049f2bf0028c5143f07d8278ede1b990378289195d4afa54f1621e138243
ISSN 0284-186X
1651-226X
IngestDate Fri Jul 11 07:43:05 EDT 2025
Mon Jul 21 06:06:41 EDT 2025
Thu Apr 24 22:52:04 EDT 2025
Wed Sep 03 16:40:42 EDT 2025
Wed Dec 25 09:08:29 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c413t-e727c049f2bf0028c5143f07d8278ede1b990378289195d4afa54f1621e138243
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ORCID 0000-0002-6539-0682
OpenAccessLink https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2020.1760349?needAccess=true
PMID 32436467
PQID 2405333249
PQPubID 23479
PageCount 7
ParticipantIDs pubmed_primary_32436467
crossref_primary_10_1080_0284186X_2020_1760349
proquest_miscellaneous_2405333249
crossref_citationtrail_10_1080_0284186X_2020_1760349
informaworld_taylorfrancis_310_1080_0284186X_2020_1760349
PublicationCentury 2000
PublicationDate 2020-08-02
PublicationDateYYYYMMDD 2020-08-02
PublicationDate_xml – month: 08
  year: 2020
  text: 2020-08-02
  day: 02
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Acta oncologica
PublicationTitleAlternate Acta Oncol
PublicationYear 2020
Publisher Taylor & Francis
Publisher_xml – name: Taylor & Francis
References Wegener D (CIT0021)
CIT0010
CIT0020
CIT0001
CIT0012
CIT0023
CIT0011
CIT0022
Leitlinienprogramm Onkologie der AWMW DKeVu, e.V DK. (CIT0004) 2018
CIT0003
CIT0014
CIT0002
CIT0013
CIT0005
CIT0016
CIT0015
CIT0007
CIT0018
CIT0006
CIT0017
CIT0009
CIT0008
CIT0019
References_xml – ident: CIT0001
  doi: 10.1371/journal.pone.0154499
– ident: CIT0013
  doi: 10.1016/S0167-8140(18)31915-7
– ident: CIT0019
  doi: 10.1016/j.radonc.2017.01.015
– ident: CIT0002
  doi: 10.1016/j.clon.2012.05.002
– ident: CIT0022
  doi: 10.1016/j.radonc.2016.04.014
– ident: CIT0017
  doi: 10.1016/j.radonc.2017.10.029
– ident: CIT0009
  doi: 10.1186/1471-2407-13-27
– ident: CIT0005
  doi: 10.1016/j.zemedi.2016.02.002
– start-page: 88
  ident: CIT0021
  publication-title: Acta Oncol
– ident: CIT0023
  doi: 10.1016/j.ijrobp.2006.07.013
– ident: CIT0003
– ident: CIT0018
  doi: 10.1088/0031-9155/60/2/549
– start-page: 1
  year: 2018
  ident: CIT0004
  publication-title: German S3-Guideline
– ident: CIT0006
  doi: 10.1016/j.radonc.2014.02.009
– ident: CIT0016
  doi: 10.1016/j.ijrobp.2009.07.1754
– ident: CIT0014
  doi: 10.1088/1361-6560/aae659
– ident: CIT0007
  doi: 10.1016/S0360-3016(00)00700-8
– ident: CIT0012
  doi: 10.1016/j.radonc.2005.06.006
– ident: CIT0015
  doi: 10.1016/j.ijrobp.2008.10.091
– ident: CIT0008
  doi: 10.1016/j.ijrobp.2009.01.062
– ident: CIT0010
  doi: 10.1016/S1470-2045(16)30102-4
– ident: CIT0011
  doi: 10.1016/j.radonc.2005.09.005
– ident: CIT0020
  doi: 10.1016/S0360-3016(00)00608-8
SSID ssj0002375
Score 2.3032694
Snippet Purpose: Cure- and toxicity rates of prostate IGRT can both be affected by ill-chosen planning target volume (PTV) margins. For dose-escalated prostate...
Cure- and toxicity rates of prostate IGRT can both be affected by ill-chosen planning target volume (PTV) margins. For dose-escalated prostate radiotherapy, we...
SourceID proquest
pubmed
crossref
informaworld
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 911
Title Target miss using PTV-based IMRT compared to robust optimization via coverage probability concept in prostate cancer
URI https://www.tandfonline.com/doi/abs/10.1080/0284186X.2020.1760349
https://www.ncbi.nlm.nih.gov/pubmed/32436467
https://www.proquest.com/docview/2405333249
Volume 59
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9NAFB5BKlW9IHbKpkHiZjnq2OMlxxaoClIQQimKuFj2LGkFtatkggS_nvdmcVyUqsDFiuwZ28n3Zfy957cQ8jpNC5aBEI9BLuuYs1rHjRQ6znnGZJNomWn0d0w_5ien_MM8m28CMm12iWnG4tfWvJL_QRX2Aa6YJfsPyPYnhR3wGfCFLSAM27_D2IZxRwDVKlpbo__T7EuMDyYZvZ9-nm0izEFhLrtmvTJRB2vEhU--jH6c1zAGvjdG7mBvGVe1-ycGo2O8i40xx7wQUKQYHyZ8LG8oWytMHcFIv4D2Dtu1qRcLuF_Lka_Yc_3b2Wb5Vwvls2xcfnvvEcBEUOc8UMs2pPtbr7Z_XTEY7x0ViQuTcyutcotrnrEY5N58sGCyrcu4j3uERycr8_kYzzZmRY61dIbjAY3LC4styMI0566xxx_1s8Oh22QnKUBfjcjO4dHbo-P-eZ2kRRZyu7Dq-rar7pHdcJ4rAuZKedvrjRQrVmZ3yR1vZdBDR5l75JZq75PdqY-jeECMYw5F5lDLHNozhyJzaGAONR11zKFD5lBgDg3MoQPmUM8cet7SwBzqmPOQnB6_m705iX3_jViAtDGxAm0rwILUSaPRNhcorvVBIcukKJVUrAEpkxZos7NJJnmt64xrlidMYWVLnj4io7Zr1RNCJ7IuuTwQuhGKK5jBy0yIEtvR5YnMm33Cw49aCV-cHnukfK9YqGHrYakQlsrDsk_G_bRLV53lpgmTIWKVsW4x7XrYVOkNc18FeCuAB1-s1a3q1qsKVDFYTUAQGPPY4d7fTqDN02uPPCN7m7_LczIyy7V6AUrXNC89VX8DaTak2w
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Target+miss+using+PTV-based+IMRT+compared+to+robust+optimization+via+coverage+probability+concept+in+prostate+cancer&rft.jtitle=Acta+oncologica&rft.au=Outaggarts%2C+Zoulikha&rft.au=Wegener%2C+Daniel&rft.au=Berger%2C+Bernhard&rft.au=Zips%2C+Daniel&rft.date=2020-08-02&rft.eissn=1651-226X&rft.spage=1&rft_id=info:doi/10.1080%2F0284186X.2020.1760349&rft_id=info%3Apmid%2F32436467&rft.externalDocID=32436467
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0284-186X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0284-186X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0284-186X&client=summon